Inhibitors of the type 2 sodium-glucose co-transporter (iSGLT2) may improve the metabolic and hemodynamic profile in patients with DM2 and heart failure.
Study Type
OBSERVATIONAL
Enrollment
100
Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)
Germans Trias i Pujol University Hospital
Badalona, Spain
Change in cardiac biomarkers
Changes in cardiac biomarkers: NTproBNP, CA125 and ST2
Time frame: 12 months
Change in quality of life: EuroQol-5D questionnaire (EuroQol five dimension questionnaire)
Changes in patient's quaility of life by 5Q questionnaire (EuroQol standardised, non-disease-specific instrument for health-related quality of life with 2 parts: first one score from 3-3-3-3 (worst) to 1-1-1-1 (best) and second one which a visual scale scores form 0 (worst)-100 (best). EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208. El EuroQol-5D: una alternativa sencilla para la medición de la calidad de vida relacionada con la salud en atención primaria. Aten Primaria 2001; 28:425-429.)
Time frame: 12 months
Improvement of pulmonary congestion
Changes in pulmonary congestion by pulmonary echocardiography
Time frame: 12 months
Improve in the 6-minute walk
Changes in functional capacity by the 6 minute-walk
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.